On Tuesday, Valneva SE (NASDAQ:VALN) revealed antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ.
The results align with Valneva’s expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated.
The three-year persistence data align with the twelve-month and two-year persistence data the company reported in December 2022 and 2023, respectively.
Also Read: European And US Vaccine Stocks Are Under Pressure – Here’s Why
Among the 278 healthy adults still enrolled in the trial, 96% maintained neutralizing antibody titers well above the seroresponse threshold three years after the single-dose vaccination. The primary endpoint was, therefore, met.
The persistence of antibodies in older adults ...